Alithea (Greek): 'the state of not being hidden'. We like to think of it as "the state of DISCOVERY"
From research to technology
Our story begins with a very concrete research need, i.e., to be able to run a large number of RNA sequencing experiments in an affordable and rapid manner.
To address this need, we set out to develop a new technology called Bulk RNA Barcoding and sequencing (BRB-seq). We published our technology in the peer-reviewed journal Genome Biology in April 2019 and, by the end of the year, our article entered the 2019 TOP 10 most read papers of the journal.
From BRB-seq to Alithea
As a corroboration of the scientific community's interest, we received several inquiries from labs and companies asking for support to establish our technology in their facilities (kits) or to run BRB-seq directly on their RNA samples (service).
The demand grew rapidly, we saw a gap in the industry, and so the decision was made to launch our own company.
Alithea Genomics was founded in May 2020 by co-founders Riccardo Dainese (CEO), Daniel Alpern (CTO), and Prof. Bart Deplancke (Scientific advisor).
At Alithea Genomics we are committed to developing solutions that simplify and streamline the generation of "big RNA data", which we believe will constitute the foundation of tomorrow's research and medicine.
Our technologies enable our clients to discover new biomarkers and develop new drugs at a fraction of the costs and time as compared to what was possible before.
Daniel Alpern CTO and co-founder
Riccardo Dainese CEO and co-founder
Frederik Decouttere Chairman of the Board
Jan Van den Berghe Board member
Kaspar Binz Board member
Roger Kung Board member
Prof. Bart Deplancke Scientific Advisor and co-founder
Reto Hartmann Business Coach